Sep 15, 2022 09:15AM
Sep 15, 2022 09:15AM
Sep 15, 2022 09:15AM
Sep 14, 2022 08:03AM
Sep 14, 2022 08:00AM
Sep 14, 2022 08:00AM
Sep 8, 2022 08:00AM Caladrius Biosciences Announces Participation in Upcoming Investor Conferences in September 2022
Sep 8, 2022 08:00AM
Aug 10, 2022 08:00AM
Aug 10, 2022 08:00AM
Aug 4, 2022 04:05PM
Aug 4, 2022 04:05PM
Aug 2, 2022 08:00AM
Aug 2, 2022 08:00AM Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease
Jul 28, 2022 08:00AM
Jul 28, 2022 08:00AM
Jul 6, 2022 08:06AM
Jul 6, 2022 08:00AM
Jul 6, 2022 08:00AM
Jun 9, 2022 08:00AM
Jun 9, 2022 08:00AM Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEND-1 in Collaboration with Australasian Gastro-Intestinal Cancer Trials Group
Jun 8, 2022 08:00AM
Jun 8, 2022 08:00AM
Jun 6, 2022 06:26AM
May 26, 2022 08:00AM
May 26, 2022 08:00AM
May 23, 2022 04:05PM
May 23, 2022 04:05PM Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction
May 23, 2022 04:05PM
May 19, 2022 08:01AM
May 19, 2022 08:00AM
May 19, 2022 08:00AM
May 18, 2022 08:00AM
May 18, 2022 08:00AM
May 5, 2022 04:05PM Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 5, 2022 04:05PM
May 2, 2022 01:08PM
Apr 28, 2022 08:00AM
Apr 28, 2022 08:00AM
Apr 27, 2022 08:00AM
Apr 27, 2022 07:01AM
Apr 27, 2022 07:00AM Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement
Apr 27, 2022 07:00AM
Mar 22, 2022 04:09PM
Mar 22, 2022 04:05PM
Mar 22, 2022 04:05PM
Nov 4, 2021 04:05PM
Nov 4, 2021 04:05PM
May 7, 2020 04:05PM Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results
May 7, 2020 04:05PM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All